custom image

Advances in Cancer Immunotherapy

August 17–19, 2020 | 10:00AM EDT | 2:00PM UTC | 4:00PM CEST*
*Program is subject to change


Cancer immunotherapy provides unprecedented long-term antitumor activity in some patients, however the majority of patients with advanced cancers only experience short-term remission. To achieve better outcomes for everyone will require a mechanistic understanding of response, and resistance, to these therapies, including immune inhibitory checkpoint blockade and T-cell engineering. These insights will provide rationale for how to best combine these therapeutic approaches for sustained clinical success.

In this virtual meeting we will tackle many of these unanswered questions in the field, including:

  • How do cancers adapt and resist T cell attack?
  • Can we better understand the tumor microenvironment to pave the way for new approaches to immunotherapy?
  • What is the rationale behind immune-oncology (IO) combinations in clinical testing?

The program highlights novel methodologies, data-analysis techniques, and tools to integrate high throughput and patient-derived sample data, revealing powerful new approaches to understand both genetic and adaptive resistance mechanisms, and ways to overcome them. The largest human experiment to date is currently underway, testing over 1,000 agents and combinations; examining preliminary results will be key to refining our approaches, and understanding of immunity in patients with cancer.

Overall, participants will gain a more comprehensive understanding of tumor immunology, and how to leverage this knowledge to outsmart tumors and achieve lasting remission in patients. In addition, the virtual event provides a platform for trainees, junior researchers, and rising stars in the field to share promising new directions that will progress the field forward, towards new and innovative breakthroughs.

Keystone Symposia conferences provide unique opportunities for trainees and junior researchers to present their work to global audiences and field leaders. The eSymposia platform continues this strong tradition of providing these critical career-development and advancement experiences for the next-generation, incorporating short talks and ePoster sessions to highlight rising stars in the field.

Pricing:

Registration for this meeting is now closed.

Deadlines:

Scholarships: Passed
Abstract Submission: Passed

#VKScancerimmuno20



Program Details



Keynote Speaker


f987c0e6d29d3fdd1ffdfba4bcaa8005.png

James P. Allison

University of Texas MD Anderson Cancer Center

Immune Checkpoint Blockade in Cancer Therapy:
New Insights into Therapeutic Mechanisms



Editors Attending This Meeting


custom image

custom image

Gaia Trincucci, PhD Scientific Editor, Journal of Experimental Medicine (JEM)
Teodoro-Pulvirenti, PhD Executive Editor, Journal of Experimental Medicine (JEM)

Speaking at this eSymposia


88e01c4cd09f2fed1549b009b8c1c6da.png

Coralie Backlund

Massachusetts Institute of Technology


custom image

Katie Campbell

University of California, Los Angeles


33477b9ef26da02c5193a4d1e99e0aa1.png

Yvonne Y. Chen

University of California, Los Angeles


df96b7b7e08ae32cb68d713cea0747d8.png

Shira Tabachnick-Cherny

University of Washington


cf448db595d79726bb11f3750c4741fd.png

AHyun Choi

Novartis Institutes for BioMedical Research


fdc3c542fa0d0db90eecbcba6f3b63ae.png

Kelli Connolly

Yale University


de38b91494ecfb85c6732ae3efab32f2.png

Nadine A. Defranoux

Parker Institute for Cancer Immunotherapy


32e44f9bdce75ec56ed8a3a0206ca087.png

James R. Heath

Institute for Systems Biology





Sponsors



custom image

custom image

custom image

custom image

custom image

custom image

custom image

custom image

custom image

 

custom image

 



Additional Support



custom image

custom image

Funding for this conference was made possible (in part) by 1R13CA246936-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.




Media In-Kind Sponsors



EMBO

JEM and JCB

Frontiers

custom image





The views expressed in this eSymposia are those of the participants and not necessarily of the participants’ organizations or of Keystone Symposia.






Related Keystone Symposia In-Person Meetings

Explore all cancer-related meetings on the Keystone Symposia website.

custom image

custom image

custom image






Donate to Keystone Symposia


custom image